Scholarlink

<p>Pancreatic ductal adenocarcinoma (PDAC) remains a malignancy with limited 5-year overall survival, but recent advances in maximizing chemotherapy delivery has offered some improvement across all stages. Delivery of induction chemotherapy for localized PDAC has several putative benefits, including early treatment of occult metastases, pragmatically ensuring all patients receive systemic therapy, and improved R0 resection rates. While neoadjuvant therapy has become widely accepted in borderline resectable clinical stage, its role in patients with resectable disease is less clear. This Landmark Series article discusses key studies informing the ongoing debate about neoadjuvant therapy for resectable PDAC, both published and ongoing. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Landmark Series: Neoadjuvant Therapy for Resectable Pancreatic Cancer

  • 期刊论文

  • 发表日期：

    2025年7月7日

查看全文
  • Chelsea F. Cardell,
  • Esther N. Dekker,
  • Matthew H. G. Katz,
  • Ching-Wei D. Tzeng

摘要

Pancreatic ductal adenocarcinoma (PDAC) remains a malignancy with limited 5-year overall survival, but recent advances in maximizing chemotherapy delivery has offered some improvement across all stages. Delivery of induction chemotherapy for localized PDAC has several putative benefits, including early treatment of occult metastases, pragmatically ensuring all patients receive systemic therapy, and improved R0 resection rates. While neoadjuvant therapy has become widely accepted in borderline resectable clinical stage, its role in patients with resectable disease is less clear. This Landmark Series article discusses key studies informing the ongoing debate about neoadjuvant therapy for resectable PDAC, both published and ongoing.